Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOS1SIP
- Development stage
- Discontinued
- Lead developer
- Polymun Scientific
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MOS1SIP is part of a group of HIV Env mosaic immunogens, which are therapeutic vaccines designed to stimulate the immune system against HIV. These immunogens are used in combination with adjuvants like Monophosphoryl lipid A liposomes (MPLA-5) to enhance immune response. The primary indication is for HIV infections, focusing on preventive vaccine development. Developed by Polymun Scientific Immunbiologische Forschung GmbH.
- Other names
- HIV Env Mosaic immunogens
02
Targets
BCR (Immunoglobulin G B Cell Receptor)T-cell receptor recognizing HIV-1 Env-derived peptides presented on MHCTLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on MOS1SIP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOS1SIP.